RCT: In patients with acromegaly who previously tolerated and responded to both regimens, oral octreotide was non-inferior for maintaining biochemical response and symptomatic control compared to injectable somatostatin receptor ligands.

Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)